Omacor (omega-3-acid ethyl esters)

Practical Diabetes International

Volumn 27, Issue 1, 2010, Pages 38-39

  Sears, Alison V ^a   Walker, Simon W ^a   Ho, Clement K M ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANTIARRHYTHMIC ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; FATTY ACID OXIDATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; HYPERTRIGLYCERIDEMIA; LICENSING; NONHUMAN; RISK REDUCTION; SHORT SURVEY; UPREGULATION;

EID: 76649129038     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1439     Document Type: Short Survey

References (4)

1. Hoy S, Keating GM. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 2009; 69(8): 1077-1105.
2. Harris W, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidology 2006; 17: 387-393.
3. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
4. Hartweg J, Perera R, Montori VM, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (2): CD003205. DOI: 10.1002/14651858. CD003205.pub2.